Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 189041 | 7.87 |
09:34 ET | 2310 | 7.77 |
09:36 ET | 1400 | 7.77 |
09:38 ET | 1300 | 7.85 |
09:39 ET | 1300 | 7.82 |
09:41 ET | 1159 | 7.751 |
09:43 ET | 1493 | 7.77 |
09:45 ET | 17752 | 7.76 |
09:48 ET | 1300 | 7.81 |
09:50 ET | 2810 | 7.825 |
09:52 ET | 1400 | 7.82 |
09:54 ET | 5372 | 7.84 |
09:56 ET | 4578 | 7.83 |
09:57 ET | 10823 | 7.79 |
09:59 ET | 11466 | 7.82 |
10:01 ET | 6327 | 7.865 |
10:03 ET | 5500 | 7.84 |
10:06 ET | 2597 | 7.835 |
10:08 ET | 16222 | 7.83 |
10:10 ET | 9551 | 7.85 |
10:12 ET | 6728 | 7.88 |
10:14 ET | 6402 | 7.85 |
10:15 ET | 19765 | 7.9 |
10:17 ET | 9691 | 7.9201 |
10:19 ET | 12242 | 7.92 |
10:21 ET | 15864 | 7.94 |
10:24 ET | 5100 | 7.945 |
10:26 ET | 4115 | 7.93 |
10:28 ET | 2661 | 7.89 |
10:30 ET | 2277 | 7.87 |
10:32 ET | 17246 | 7.85 |
10:33 ET | 892 | 7.85 |
10:35 ET | 7468 | 7.83 |
10:37 ET | 33688 | 7.94 |
10:39 ET | 42550 | 8.015 |
10:42 ET | 20543 | 7.98 |
10:44 ET | 2800 | 8 |
10:46 ET | 7982 | 8 |
10:48 ET | 13835 | 8.03 |
10:50 ET | 14767 | 8.065 |
10:51 ET | 10976 | 8.03 |
10:53 ET | 7098 | 8.07 |
10:55 ET | 14911 | 8.1292 |
10:57 ET | 9460 | 8.12 |
11:00 ET | 3542 | 8.1101 |
11:02 ET | 5563 | 8.115 |
11:04 ET | 24330 | 8.0516 |
11:06 ET | 5587 | 8.02 |
11:08 ET | 13487 | 8.01 |
11:09 ET | 1971 | 8 |
11:11 ET | 3382 | 8.01 |
11:13 ET | 1446 | 8.02 |
11:15 ET | 3904 | 8.02 |
11:18 ET | 6933 | 8.0732 |
11:20 ET | 5924 | 8.055 |
11:22 ET | 717 | 8.06 |
11:24 ET | 2263 | 8.06 |
11:26 ET | 2931 | 8.1 |
11:27 ET | 3313 | 8.08 |
11:29 ET | 8216 | 8.075 |
11:31 ET | 6748 | 8.06 |
11:33 ET | 1634 | 8.06 |
11:36 ET | 4415 | 8.05 |
11:38 ET | 1458 | 8.04 |
11:40 ET | 8556 | 8.015 |
11:42 ET | 1400 | 7.99 |
11:44 ET | 14952 | 7.94 |
11:45 ET | 5464 | 7.955 |
11:47 ET | 11377 | 7.945 |
11:49 ET | 24351 | 7.96 |
11:51 ET | 3553 | 7.98 |
11:54 ET | 485 | 7.9824 |
11:56 ET | 3045 | 7.97 |
11:58 ET | 595 | 7.98 |
12:00 ET | 500 | 7.98 |
12:02 ET | 6959 | 8 |
12:03 ET | 5955 | 7.96 |
12:05 ET | 500 | 7.99 |
12:07 ET | 8990 | 7.95 |
12:09 ET | 4947 | 7.96 |
12:12 ET | 6879 | 7.96 |
12:14 ET | 1894 | 7.99 |
12:16 ET | 3195 | 7.98 |
12:18 ET | 1700 | 7.95 |
12:20 ET | 2050 | 7.91 |
12:21 ET | 1804 | 7.95 |
12:23 ET | 1346 | 7.95 |
12:25 ET | 2180 | 7.96 |
12:27 ET | 8219 | 7.92 |
12:30 ET | 3998 | 7.94 |
12:32 ET | 3164 | 7.97 |
12:34 ET | 2402 | 7.98 |
12:36 ET | 11359 | 7.97 |
12:38 ET | 3439 | 7.99 |
12:39 ET | 6965 | 7.97 |
12:41 ET | 800 | 7.995 |
12:43 ET | 1497 | 7.995 |
12:45 ET | 1478 | 8.02 |
12:48 ET | 12146 | 8 |
12:50 ET | 1900 | 7.98 |
12:52 ET | 1147 | 7.97 |
12:54 ET | 15045 | 7.95 |
12:56 ET | 6284 | 7.93 |
12:57 ET | 1384 | 7.95 |
12:59 ET | 4058 | 7.95 |
01:03 ET | 3343 | 7.98 |
01:06 ET | 1586 | 8 |
01:08 ET | 3438 | 7.98 |
01:10 ET | 958 | 7.98 |
01:12 ET | 1857 | 8 |
01:14 ET | 536 | 7.99 |
01:15 ET | 2896 | 7.985 |
01:17 ET | 3813 | 7.99 |
01:19 ET | 9148 | 7.95 |
01:21 ET | 3315 | 7.96 |
01:24 ET | 2715 | 7.955 |
01:26 ET | 5792 | 7.94 |
01:28 ET | 900 | 7.94 |
01:30 ET | 20728 | 7.93 |
01:32 ET | 3751 | 7.94 |
01:33 ET | 6808 | 7.95 |
01:35 ET | 2016 | 7.95 |
01:37 ET | 2230 | 7.95 |
01:39 ET | 8790 | 7.945 |
01:42 ET | 5609 | 7.94 |
01:44 ET | 2299 | 7.93 |
01:46 ET | 2698 | 7.93 |
01:48 ET | 3535 | 7.94 |
01:50 ET | 19582 | 7.94 |
01:51 ET | 2620 | 7.94 |
01:53 ET | 9368 | 7.94 |
01:55 ET | 3103 | 7.94 |
01:57 ET | 3239 | 7.95 |
02:00 ET | 8462 | 7.935 |
02:02 ET | 1143 | 7.94 |
02:04 ET | 3699 | 7.93 |
02:06 ET | 1641 | 7.93 |
02:08 ET | 2685 | 7.93 |
02:09 ET | 2073 | 7.93 |
02:11 ET | 4596 | 7.93 |
02:13 ET | 24003 | 7.98 |
02:15 ET | 4759 | 7.98 |
02:18 ET | 15523 | 7.96 |
02:20 ET | 4302 | 7.96 |
02:22 ET | 1189 | 7.94 |
02:24 ET | 1736 | 7.91 |
02:26 ET | 2101 | 7.96 |
02:27 ET | 4491 | 7.95 |
02:29 ET | 5912 | 7.93 |
02:31 ET | 2684 | 7.94 |
02:33 ET | 4037 | 7.92 |
02:36 ET | 3492 | 7.91 |
02:38 ET | 8428 | 7.9 |
02:40 ET | 5972 | 7.9 |
02:42 ET | 3808 | 7.93 |
02:44 ET | 3348 | 7.925 |
02:45 ET | 3436 | 7.92 |
02:47 ET | 2488 | 7.92 |
02:49 ET | 7190 | 7.92 |
02:51 ET | 3500 | 7.91 |
02:54 ET | 2359 | 7.93 |
02:56 ET | 4698 | 7.94 |
02:58 ET | 2402 | 7.94 |
03:00 ET | 6884 | 7.93 |
03:02 ET | 2521 | 7.93 |
03:03 ET | 2922 | 7.95 |
03:05 ET | 2772 | 7.94 |
03:07 ET | 7182 | 7.94 |
03:09 ET | 21010 | 7.98 |
03:12 ET | 18651 | 7.97 |
03:14 ET | 5739 | 7.995 |
03:16 ET | 6385 | 7.995 |
03:18 ET | 8566 | 8 |
03:20 ET | 9720 | 8 |
03:21 ET | 10462 | 8 |
03:23 ET | 24280 | 7.99 |
03:25 ET | 6956 | 8 |
03:27 ET | 12029 | 7.975 |
03:30 ET | 98241 | 7.95 |
03:32 ET | 16939 | 7.94 |
03:34 ET | 19114 | 7.925 |
03:36 ET | 12693 | 7.9 |
03:38 ET | 25494 | 7.84 |
03:39 ET | 29256 | 7.86 |
03:41 ET | 13473 | 7.82 |
03:43 ET | 17107 | 7.81 |
03:45 ET | 32472 | 7.835 |
03:48 ET | 27703 | 7.82 |
03:50 ET | 30873 | 7.845 |
03:52 ET | 56615 | 7.855 |
03:54 ET | 65368 | 7.89 |
03:56 ET | 67113 | 7.96 |
03:57 ET | 40838 | 7.93 |
03:59 ET | 5854431 | 7.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.6B | -47.9x | --- |
Viking Therapeutics Inc | 5.8B | -56.7x | --- |
Madrigal Pharmaceuticals Inc | 5.9B | -12.1x | --- |
Nuvalent Inc | 5.1B | -32.9x | --- |
BridgeBio Pharma Inc | 5.1B | -8.5x | --- |
Immunitybio Inc | 5.0B | -6.9x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.